Find trials
Consejos para buscar

Cortical Excitability and Inhibition in MDD

Overview

Información sobre este estudio

The purpose of this study is to learn if measures of brain activity are different in children and adolescents with depression who are in different stages of treatment. This is important because it may identify a biological marker for depression that could one day be used to identify depressed children who would benefit from certain treatments (medications for example), or to monitor how well treatments are working. Brain activity measures(known as cortical excitability and inhibition) will be collected by Transcranial Magnetic Stimulation (TMS). TMS is a noninvasive (no surgery or implants) brain stimulation technology which can make parts of the brain work without putting any wires or chemicals into the body. Measurements will take place over one 3-hour visit. This study does not provide any form of treatment.

*There is an optional portion of the study that uses a brain scan to gather measures of brain structure and brain chemicals. The brain scan is called magnetic resonance and spectroscopy (MRI/MRS). MRI/MRS uses magnetic fields to study the structure of the brain and brain chemicals. The PI will determine eligibility for the MRI/MRS portion of the study.

Elegibilidad para la participación

Los requisitos de elegibilidad de los participantes incluyen la edad, el sexo, el tipo y el estadio de la enfermedad, y los problemas de salud o tratamientos previos. Las pautas difieren de un estudio a otro e identifican quiénes pueden o no pueden participar. No hay garantía de que cada persona elegible que desee participar en un ensayo se inscribirá. Comunícate con el equipo del estudio para analizar la elegibilidad del estudio y la posible participación.

Inclusion Criteria:

  • Adolescents from the ages of 13 to 21, male or female.
  • Subjects with MDD (groups 2, 3, and 4):
  • Must have a Children's Depression Rating Scale, Revised (CDRS-R) score of 40 or higher
  • Must have a Clinical Global Impression-Severity scale (CGI-S) score of 4 or higher.
  • Group 1: (50 subjects): Subjects who have mild (CDRS-R score < 40) but clinically significant depression.
  • Group 2: (50 subjects): Subjects with moderate to severe MDD who have not yet initiated treatment with an SSRI.
  • Group 3: (50 subjects): Subjects with moderate to severe MDD that has responded to treatment with an SSRI.
  • Group 4: (50 subjects): Subjects with moderate to severe MDD which has not responded to treatment with an SSRI.
  • Capable of providing informed assent (consent if age 18) in addition to consent by parent or guardian.
  • Subjects and at least 1 parent must be fluent in English.

Exclusion Criteria:

  • Primary Axis I or II disorder other than MDD.
  • Unprovoked seizure history, seizure disorder, history of febrile seizures, family history of epilepsy.
  • Any significant findings on the TMS Adult Safety Screen (TASS) or contraindications to MRI/MRS
  • Subjects who are judged by the Principal Investigator to be at imminent risk for self harm or suicide as indicated by interview or C-SSRS.
  • Pregnancy or suspected pregnancy in females.
  • Metal in the head (except the mouth*), implanted medication pumps, cardiac pacemaker. * Subjects with braces will be excluded from MRI/MRS portion of study only
  • Prior brain surgery.
  • Risk for increased intracranial pressure such as a brain tumor.
  • Any unstable medical condition.

Sedes participantes de Mayo Clinic

Los estatus de los estudios cambian con frecuencia. Comunícate con el equipo del estudio para obtener la información más actualizada acerca de la posibilidad de participar.

Sede de Mayo Clinic Estatus

Rochester, Minn.

Investigador principal de Mayo Clinic

Paul Croarkin, D.O., M.S.

Cerrado para la inscripción

More information

Publicaciones

Publications are currently not available

Otros temas en investigación

.
CLS-20112075

Mayo Clinic Footer